| abstract |
The invention relates to substituted pyridine derivatives. In particular, the invention relates to compounds corresponding to the formulas: or their pharmaceutically acceptable salts. The compounds of the invention are selective DNMT1 inhibitors and can be used in the treatment of malignant neoplasm, precancerous conditions, beta hemoglobinopathies, sickle cell disease, sickle cell anemia and beta thalassemia, and diseases associated with DNMT1 inhibition. The invention further relates to pharmaceutical compositions / combinations containing a compound of the invention as an active ingredient. The invention further relates to methods for inhibiting DNMT1 activity. |